30
Participants
Start Date
August 23, 2022
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2025
Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
RECRUITING
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou
Shanghai Virogin Biotech Co., Ltd.
INDUSTRY